Clincosm LogoSign in Get a demo

Follicular Lymphoma

Showing NaN - NaN of 29
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
  • Birmingham, Alabama
  • +24 more
Nov 21, 2022

DLBCL, Follicular Lymphoma Trial in United States (Epcoritamab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Fountain Valley, California
  • +38 more
Jul 27, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • EO2463
  • +2 more
  • Boston, Massachusetts
  • +9 more
Jul 26, 2022

DLBCL, Follicular Lymphoma Trial in Worldwide (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
  • +7 more
  • Birmingham, Alabama
  • +61 more
Apr 13, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (Ibrutinib)

Enrolling by invitation
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +165 more
Mar 24, 2022

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Follicular Lymphoma Trial in United States (Rituximab, Utomilumab, Avelumab)

Active, not recruiting
  • Follicular Lymphoma
  • Duarte, California
  • +5 more
Mar 17, 2022

Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)

Recruiting
  • Follicular Lymphoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2022

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022

Follicular Lymphoma Trial in Boston (Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells)

Active, not recruiting
  • Follicular Lymphoma
  • Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Feb 28, 2022

Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma Trial in United States (Haploidentical Bone Marrow

Completed
Has Results
  • Acute Lymphocytic Leukemia
  • +6 more
  • Haploidentical Bone Marrow Transplant
  • Double Umbilical Cord Blood Transplant
  • Birmingham, Alabama
  • +38 more
Nov 2, 2021

Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma Trial in Canada, United States (ABT-263)

Completed
  • Chronic Lymphoid Leukemia
  • +5 more
  • Los Angeles, California
  • +11 more
Jul 28, 2021

Follicular Lymphoma Trial in Japan, United States (Rituximab, Lenalidomide, Rituximab-CHOP)

Active, not recruiting
  • Follicular Lymphoma
  • Chandler, Arizona
  • +46 more
Jan 8, 2021

Follicular Lymphoma Trial in Worldwide (HCD122)

Completed
  • Follicular Lymphoma
  • Boston, Massachusetts
  • +11 more
Dec 6, 2020

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma Trial in Canada, United States (Entospletinib

Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Entospletinib MM
  • Entospletinib SDD
  • Birmingham, Alabama
  • +47 more
Nov 2, 2020

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma Trial in United States (SNS-062)

Terminated
  • Chronic Lymphocytic Leukemia
  • +7 more
  • Orange, California
  • +10 more
Oct 15, 2020

Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1 Trial in Boston (Umbralisib, Rituximab)

Recruiting
  • Lymphoma
  • +6 more
  • Boston, Massachusetts
  • +1 more
Aug 31, 2020

B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma Trial in

Completed
Has Results
  • B-cell Chronic Lymphocytic Leukemia
  • +9 more
  • Stanford, California
  • +15 more
May 14, 2020

Patients Previously Treated With a Juno CAR T-Cell Product

Terminated
  • Non Hodgkin Lymphoma
  • +5 more
  • JCAR017
  • JCARH125
  • Duarte, California
  • +1 more
Apr 30, 2020

Follicular Lymphoma Trial in Worldwide (IXAZOMIB)

Completed
Has Results
  • Follicular Lymphoma
  • Boston, Massachusetts
  • +13 more
Oct 7, 2019